Generic Exforge market getting heated

Published: 2013-10-01 06:59:00

Updated: 2013-10-01 06:59:00

Starting in October, CJ Pharmaceutical Unit will gear up to enter the domestic combination-form hypertensive drug market with a tool of its incrementally modified drug Exone (valsartan and amlodipine adipate) in a bid to challenge Novartis’s Exforge (valsartan and amlodipine besylate).

This on...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK